Locanabio, Inc. logo

Locanabio, Inc.

Creating RNA-targeting gene therapies to treat devastating diseases

7 employees · est. 2016 · San Diego, United States

VS
Precede Biosciences logo

Precede Biosciences

Precede Bio is impacting precision medicine with a first-in-class 🩸 liquid biopsy platform

61 employees · est. 2021 · United States

Locanabio, Inc. is the older company (2016 vs 2021); Precede Biosciences is the larger of the two.

Side-by-Side Comparison

Locanabio, Inc. Precede Biosciences
Founded
2016 older 2021
Headquarters
San Diego, United States United States
Employees
7 61 larger
Industry
Biotechnology, Health Care, Health and Wellness Not tracked yet
Funding Stage
Series B Series A
Total Funding
$155.55M $120.50M
Funding Rounds
3 2
Services
Not tracked yet Liquid biopsy platform development, Epigenomic analysis and profiling, Diagnostics for cancer and other diseases, Therapeutic target identification, Strategic partnerships with pharmaceutical companies, R&D in precision medicine
Target Customers
Not tracked yet Pharmaceutical companies, Biotech firms, Oncology research institutions, Healthcare providers, Medical diagnostic labs
Taxonomy
RNA-targeting Gene Therapy, Genetic Medicine, Neurodegenerative Diseases, Neuromuscular Diseases, Rare Genetic Diseases, RNA Biology, Gene Editing, Genomic Medicine, RNA-mediated Disease, Drug Development, Neurological Disorders Precision Medicine, Liquid Biopsy, Transcriptional Biology, Chromatin Profiling, DNA Methylome, Genomic Medicine, Diagnostic Tests, Drug Development, Cancer Diagnosis, Minimally Invasive Diagnostics, Disease Biology, Machine Learning In Genomics, Artificial Intelligence In Healthcare, Oncology, Genomic Profiling
Website
locanabio.com precede.bio
Locanabio, Inc. logo

About Locanabio, Inc.

Locanabio, Inc., founded in 2016, is at the forefront of developing RNA-targeting gene therapies to address significant unmet medical needs. Their innovative approach focuses on correcting disease-causing RNA, utilizing a proprietary platform that includes advanced systems like snRNA, Cas13d, and PU...

Precede Biosciences logo

About Precede Biosciences

Precede Biosciences, founded in 2021, is at the forefront of precision medicine with its innovative first-in-class liquid biopsy platform. With headquarters in the United States, the company stands out for its commitment to enhance the medical community's understanding of disease-defining biology, o...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Locanabio, Inc. and Precede Biosciences — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Locanabio, Inc. and Precede Biosciences — by email.

Frequently Asked Questions

Locanabio, Inc. — Creating RNA-targeting gene therapies to treat devastating diseases. Precede Biosciences — Precede Bio is impacting precision medicine with a first-in-class 🩸 liquid biopsy platform . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Locanabio, Inc. has raised $155.55M while Precede Biosciences has raised $120.50M.
Locanabio, Inc. and Precede Biosciences operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Locanabio, Inc. with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy